Adenylyl cyclase 6 deletion increases mortality during sustained β-adrenergic receptor stimulation

Journal of Molecular and Cellular Cardiology

Volumn 60, Issue 1, 2013, Pages 60-67

  Tang, Tong ^a,c,d   Lai, N Chin ^a,c   Wright, Adam T ^b   Gao, Mei Hua ^a,c   Lee, Paul ^a   Guo, Tracy ^c   Tang, Ruoying ^c   McCulloch, Andrew D ^a,b   Hammond, H Kirk ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d NONE   (United States)

Author keywords

CAMP; Connexin 43; LV function; Ventricular conduction velocity

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE 6; CONNEXIN 43; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ISOPRENALINE; UNCLASSIFIED DRUG;

AC6 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BETA ADRENERGIC STIMULATION; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; FETUS; GENE; GENE DELETION; GENE EXPRESSION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PR INTERVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QRS COMPLEX;

MURINAE; MUS;

EID: 84877094010     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.04.005     Document Type: Article

References (36)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
2. Bristow M.R., Ginsburg R., Minobe W., Cubicciotti R.S., Sageman W.S., Lurie K., et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982, 307:205-211.
3. Mudd J.O., Kass D.A. Tackling heart failure in the twenty-first century. Nature 2008, 451:919-928.
4. Houser S.R., Margulies K.B., Murphy A.M., Spinale F.G., Francis G.S., Prabhu S.D., et al. Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res 2012, 111:131-150.
5. Bisognano J.D., Weinberger H.D., Bohlmeyer T.J., Pende A., Raynolds M.V., Sastravaha A., et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000, 32:817-830.
6. Engelhardt S., Hein L., Wiesmann F., Lohse M.J. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999, 96:7059-7064.
7. Liggett S.B., Tepe N.M., Lorenz J.N., Canning A.M., Jantz T.D., Mitarai S., et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000, 101:1707-1714.
8. Iwase M., Uechi M., Vatner D.E., Asai K., Shannon R.P., Kudej R.K., et al. Cardiomyopathy induced by cardiac Gs alpha overexpression. Am J Physiol 1997, 272:H585-H589.
9. Roth D.M., Bayat H., Drumm J.D., Gao M.H., Swaney J.S., Ander A., et al. Adenylyl cyclase increases survival in cardiomyopathy. Circulation 2002, 105:1989-1994.
10. Roth D.M., Gao M.H., Lai N.C., Drumm J., Dalton N., Zhou J.Y., et al. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 1999, 99:3099-3102.
11. Tang T., Gao M.H., Lai N.C., Firth A.L., Takahashi T., Guo T., et al. Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling. Circulation 2008, 117:61-69.
12. El-Armouche A., Wittkopper K., Degenhardt F., Weinberger F., Didie M., Melnychenko I., et al. Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc Res 2008, 80:396-406.
13. De Windt L.J., Lim H.W., Bueno O.F., Liang Q., Delling U., Braz J.C., et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 2001, 98:3322-3327.
14. Nakayama H., Bodi I., Correll R.N., Chen X., Lorenz J., Houser S.R., et al. alpha1G-dependent T-type Ca2+ current antagonizes cardiac hypertrophy through a NOS3-dependent mechanism in mice. J Clin Invest 2009, 119:3787-3796.
15. Lim B.K., Xiong D., Dorner A., Youn T.J., Yung A., Liu T.I., et al. Coxsackievirus and adenovirus receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the murine heart. J Clin Invest 2008, 118:2758-2770.
16. Takahashi T., Tang T., Lai N.C., Roth D.M., Rebolledo B., Saito M., et al. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation 2006, 114:388-396.
17. Tang T., Lai N.C., Hammond H.K., Roth D.M., Yang Y., Guo T., et al. Adenylyl cyclase 6 deletion reduces left ventricular hypertrophy, dilation, dysfunction, and fibrosis in pressure-overloaded female mice. J Am Coll Cardiol 2010, 55:1476-1486.
18. Lai N.C., Roth D.M., Gao M.H., Tang T., Dalton N., Lai Y.Y., et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 2004, 110:330-336.
19. Tang T., Gao M.H., Roth D.M., Guo T., Hammond H.K. Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy. Am J Physiol Heart Circ Physiol 2004, 287:H1906-H1912.
20. Sastry A., Arnold E., Gurji H., Iwasa A., Bui H., Hassankhani A., et al. Cardiac-directed expression of adenylyl cyclase VI facilitates atrioventricular nodal conduction. J Am Coll Cardiol 2006, 48:559-565.
21. Timofeyev V., He Y., Tuteja D., Zhang Q., Roth D.M., Hammond H.K., et al. Cardiac-directed expression of adenylyl cyclase reverses electrical remodeling in cardiomyopathy. J Mol Cell Cardiol 2006, 41:170-181.
22. Severs N.J., Bruce A.F., Dupont E., Rothery S. Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res 2008, 80:9-19.
23. Solan J.L., Lampe P.D. Connexin43 phosphorylation: structural changes and biological effects. Biochem J 2009, 419:261-272.
24. Guerrero P.A., Schuessler R.B., Davis L.M., Beyer E.C., Johnson C.M., Yamada K.A., et al. Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. J Clin Invest 1997, 99:1991-1998.
25. Chen H.H., Baty C.J., Maeda T., Brooks S., Baker L.C., Ueyama T., et al. Transcription enhancer factor-1-related factor-transgenic mice develop cardiac conduction defects associated with altered connexin phosphorylation. Circulation 2004, 110:2980-2987.
26. Remo B.F., Qu J., Volpicelli F.M., Giovannone S., Shin D., Lader J., et al. Phosphatase-resistant gap junctions inhibit pathological remodeling and prevent arrhythmias. Circ Res 2011, 108:1459-1466.
27. Glukhov A.V., Fedorov V.V., Kalish P.W., Ravikumar V.K., Lou Q., Janks D., et al. Conduction remodeling in human end-stage nonischemic left ventricular cardiomyopathy. Circulation 2012, 125:1835-1847.
28. Mueller E.E., Momen A., Masse S., Zhou Y.Q., Liu J., Backx P.H., et al. Electrical remodelling precedes heart failure in an endothelin-1-induced model of cardiomyopathy. Cardiovasc Res 2011, 89:623-633.
29. Xue Y., Ren J., Gao X., Jin C., Wen L., Yao X. GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. Mol Cell Proteomics 2008, 7:1598-1608.
30. Shah M.M., Martinez A.M., Fletcher W.H. The connexin43 gap junction protein is phosphorylated by protein kinase A and protein kinase C: in vivo and in vitro studies. Mol Cell Biochem 2002, 238:57-68.
31. Britz-Cunningham S.H., Shah M.M., Zuppan C.W., Fletcher W.H. Mutations of the Connexin43 gap-junction gene in patients with heart malformations and defects of laterality. N Engl J Med 1995, 332:1323-1329.
32. Gutstein D.E., Morley G.E., Tamaddon H., Vaidya D., Schneider M.D., Chen J., et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res 2001, 88:333-339.
33. Shah M., Akar F.G., Tomaselli G.F. Molecular basis of arrhythmias. Circulation 2005, 112:2517-2529.
34. Kawara T., Derksen R., de Groot J.R., Coronel R., Tasseron S., Linnenbank A.C., et al. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation 2001, 104:3069-3075.
35. Rohr S. Arrhythmogenic implications of fibroblast-myocyte interactions. Circ Arrhythm Electrophysiol 2012, 5:442-452.
36. Sun Y., Weber K.T. Animal models of cardiac fibrosis. Methods Mol Med 2005, 117:273-290.